To make an appointment, please call 1-800-KARMANOS (1-800-527-6266) or request an appointment online
As a leader in cancer research, Karmanos is able to offer patients access to innovative treatments and clinical trials that are often times not available anywhere else.
To offer hope and longer life to patients with all types of cancer, Karmanos offers the latest types of therapy through our clinical trials program. Through clinical trials, we are creating new knowledge about how therapies fight cancer and provide national leadership in testing these new therapies.
We understand that cancer is a complex disease that demands complex care. We provide each patient with a dynamic, carefully constructed treatment plan focused on their specific cancer and their unique needs.
We listen to you to design a plan that provides you with respect, compassionate care and is responsive to your emotional and practical concerns.
The underlying mission of the Molecular Therapeutics (MT) Program is to translate laboratory findings to the clinic so as to improve the lives of patients with cancer by identifying new molecules, targets and strategies for treating cancer. This highly interactive program includes a cross section of laboratory-based scientists and physicians at Karmanos who meet regularly through programmatic activities, and serve as co-investigators on research grants and investigator-initiated clinical trials.
The MT Program’s overriding goal is to integrate basic and translational scientists working broadly in areas of drug development, new or established therapeutic targets or pathways, and cellular and genetic biomarkers of cancer, with physicians conducting interventional treatment trials at the Karmanos Cancer Institute.
The MT Program leadership actively supports:
Molecular Therapeutics Program Leader Barbara Ann Karmanos Cancer Institute Professor, Department of Oncology Wayne State University School of Medicine gey@karmanos.org
Molecular Therapeutics Program Co-Leader Barbara Ann Karmanos Cancer Institute Professor, Departments of Chemistry and Oncology Wayne State University chekmenev@wayne.edu
Molecular Therapeutics Program Co-Leader Thoracic Oncology Multidisciplinary Team Leader Barbara Ann Karmanos Cancer Institute Associate Professor, Departments of Medicine and Oncology Wayne State University School of Medicine mamdanih@karmanos.org
Of all the many forms of cancer and the endless devastation they cause, lung cancer could be considered the most devastating, the most impactful. ...
For 30 years, Michael Cher, M.D. , urologic oncologist, chief of Urology and member of the Genitourinary Oncology Multidisciplinary Team (MDT), ha...
“If you care about your life and your family members, get the screenings because they are important." Lung cancer is still the leading cause of ca...